RT Journal Article
SR Electronic
T1 The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
JF Neurosciences Journal
JO Neurosciences (Riyadh)
FD Prince Sultan Military Medical City
SP 77
OP 84
DO 10.17712/nsj.2023.2.20220133
VO 28
IS 2
A1 Haythum O. Tayeb
A1 Roaa A. Khallaf
A1 Taim A. Muayqil
A1 Walid A. Alkeridy
A1 Fawwaz S. Alibrahim
A1 Omar A. Alfaify
A1 Najeeb Qadi
A1 Frank I. Tarazi
YR 2023
UL http://nsj.org.sa/content/28/2/77.abstract
AB Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources, infrastructure, research, and clinical practice changes that must be attained to transform the patient journey and clinical pathways of AD in Saudi Arabia to enable offering AD immunotherapies in Saudi Arabia.